

26th September, 2025

To,

The Corporate Relationship Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001. <i>Scrip Code: 539523</i>	National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra East, Mumbai 400 051. <i>Scrip Symbol: ALKEM</i>
--	---

Sub: Disclosure under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended (“SEBI LODR Regulations”)

Dear Sir(s)/Madam,

This is in continuation of our earlier intimation dated 10th December, 2024, wherein the Stock Exchanges were informed about the transfer of the trade generics business of M/s. Alkem Laboratories Limited (‘the Company’) as a going concern, on a slump sale basis, to M/s. Alkem Wellness Limited, a wholly owned subsidiary of the Company, incorporated in India (“Alkem Wellness”) to be effected through a Business Transfer Agreement to be executed between the Company and Alkem Wellness.

In this regard, we wish to inform you that today i.e. 26th September, 2025, the Company has entered into a Business Transfer Agreement with Alkem Wellness, in terms of which, the said transfer of the trade generics business shall be effective from 01st October, 2025.

The above information is also available on the website of the Company at www.alkemlabs.com.

Kindly take the same on your records.

Sincerely,

For **Alkem Laboratories Limited**

Manish Narang

President – Legal, Company Secretary & Compliance Officer